Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma

Ding,Yi; Lu,Huina; Dong,Yan; Xiu,Bing; Liang,Aibin; Zhang,Wenjun

doi:10.3892/ol.2023.13854

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma

Authors:
- Yi Ding
- Huina Lu
- Yan Dong
- Bing Xiu
- Aibin Liang
- Wenjun Zhang
View Affiliations

Affiliations: Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China
Published online on: May 4, 2023 https://doi.org/10.3892/ol.2023.13854
Article Number: 268
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that arsenic trioxide (ATO) regulates lymphoma cell cycle, apoptosis, autophagy and mitochondrial activity, while it synergizes with other cytotoxic agents. In addition, ATO targets anaplastic lymphoma kinase (ALK)‑fusion oncoprotein to repress anaplastic large cell lymphoma (ALCL). The current study aimed to investigate the efficacy and safety of ATO plus etoposide, solumedrol, high‑dose cytarabine and cisplatin (ESHAP) chemotherapy compared with ESHAP chemotherapy alone in patients with relapsed or refractory (R/R) ALK⁺ ALCL. A total of 24 patients with R/R ALK⁺ ALCL were enrolled in the present study. Among them, 11 patients were treated with ATO plus ESHAP, while the remaining 13 patients received ESHAP chemotherapy alone. Subsequently, treatment response, event‑free survival (EFS), overall survival (OS) and adverse event (AEs) rates were recorded. Both complete response (72.7% vs. 53.8%; P=0.423) and objective response (81.8% vs. 69.2%; P=0.649) rates were higher in the ATO plus ESHAP group compared with the ESHAP group. However, statistical significance was not reached. In addition, EFS was significantly prolonged (P=0.047), while OS was not significantly increased (P=0.261) in the ATO plus ESHAP group compared with the ESHAP group. More specifically, the 3‑year accumulating EFS and OS rates were 59.7 and 77.1% in the ATO plus ESHAP group, respectively, and 13.8 and 59.8% in the ESHAP group, respectively. The majority of AEs, such as thrombocytopenia (81.8% vs. 46.2%; P=0.105), fever (81.8% vs. 46.2%; P=0.105) and dyspnea (36.4% vs. 15.4%; P=0.182), were more prevalent in the ATO plus ESHAP group compared with the ESHAP group. However, no statistical significance was observed. In conclusion, the current study indicated that ATO plus ESHAP chemotherapy could exert a superior efficacy compared with ESHAP chemotherapy alone in patients with R/R ALK⁺ ALCL.

View Figures

View References

1	Zhang XR, Chien PN, Nam SY and Heo CY: Anaplastic large cell lymphoma: Molecular pathogenesis and treatment. Cancers (Basel). 14:16502022. View Article : Google Scholar : PubMed/NCBI
2	Leventaki V, Bhattacharyya S and Lim MS: Pathology and genetics of anaplastic large cell lymphoma. Semin Diagn Pathol. 37:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
3	Kaseb H, Mukkamalla SKR and Rajasurya V: Anaplastic large cell lymphoma. StatPearls Treasure Island (FL): 2022
4	Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, et al: ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 111:5496–5504. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, et al: ALK-positive anaplastic large-cell lymphoma in adults: An individual patient data pooled analysis of 263 patients. Haematologica. 104:e562–e565. 2019. View Article : Google Scholar : PubMed/NCBI
6	Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, et al: Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. Eur J Cancer. 83:146–153. 2017. View Article : Google Scholar : PubMed/NCBI
7	Wang QQ, Jiang Y and Naranmandura H: Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics. 12:326–336. 2020. View Article : Google Scholar : PubMed/NCBI
8	Wahiduzzaman M, Ota A and Hosokawa Y: Novel mechanistic insights into the anti-cancer mode of arsenic trioxide. Curr Cancer Drug Targets. 20:115–129. 2020. View Article : Google Scholar : PubMed/NCBI
9	Li Z, Chen Q, Zhang W, Si G, Li J, Jiao D and Han X: Efficacy and safety of the arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021:55657932021. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Pan D, Yang H, Huang J, He Z, Li H and Li D: Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 99:e229502020. View Article : Google Scholar : PubMed/NCBI
11	Kutny MA, Alonzo TA, Abla O, Rajpurkar M, Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, et al: Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children's oncology group AAML1331 trial. JAMA Oncol. 8:79–87. 2022. View Article : Google Scholar : PubMed/NCBI
12	Zhong L, Xu F and Chen F: Arsenic trioxide induces the apoptosis and decreases NF-κB expression in lymphoma cell lines. Oncol Lett. 16:6267–6274. 2018.PubMed/NCBI
13	Li XY, Li Y, Zhang L, Liu X, Feng L and Wang X: The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β-catenin pathway and DNA methyltransferase-1. Oncol Rep. 38:3114–3120. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li HM, Long Y, Qing C, Yu M, Li ZH, Zhang XM, Li XJ, Chen YJ, Zhang YL and Liang Y: Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res. 19:149–163. 2011. View Article : Google Scholar : PubMed/NCBI
15	Li CL, Wei HL, Chen J, Wang B, Xie B, Fan LL and Li LJ: Arsenic trioxide induces autophagy and antitumor effects in Burkitt's lymphoma Raji cells. Oncol Rep. 32:1557–1563. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kouhpaikar H, Sadeghian MH, Rafatpanah H, Kazemi M, Iranshahi M, Delbari Z, Khodadadi F, Ayatollahi H and Rassouli FB: Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro. Iran J Basic Med Sci. 23:616–622. 2020.PubMed/NCBI
17	Yue LM, Chau D, Kwong YL and Tse E: Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein. Br J Haematol. 194:1085–1090. 2021. View Article : Google Scholar : PubMed/NCBI
18	Piao W, Chau D, Yue LM, Kwong YL and Tse E: Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. Leukemia. 31:522–526. 2017. View Article : Google Scholar : PubMed/NCBI
19	Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL and Suh C: ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: A single center experience. Korean J Intern Med. 21:159–164. 2006. View Article : Google Scholar : PubMed/NCBI
20	Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, et al: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 113:6528–6532. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al: Revised response criteria for malignant lymphoma. J Clin Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhu HH, Hu J, Lo-Coco F and Jin J: The simpler, the better: Oral arsenic for acute promyelocytic leukemia. Blood. 134:597–605. 2019. View Article : Google Scholar : PubMed/NCBI
23	Zhao H, Sun G, Kong D, Zhang Y, Shi W, Zhao M, Hong L and Qiao Z: A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. Med Oncol. 32:792015. View Article : Google Scholar : PubMed/NCBI
24	Hermine O, Dombret H, Poupon J, Arnulf B, Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, et al: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 5:130–134. 2004. View Article : Google Scholar : PubMed/NCBI
25	Marçais A, Cook L, Witkover A, Asnafi V, Avettand-Fenoel V, Delarue R, Cheminant M, Sibon D, Frenzel L, de Thé H, et al: Arsenic trioxide (As₂O₃) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology. 17:52020. View Article : Google Scholar : PubMed/NCBI
26	Tang J, Yao C, Liu Y, Yuan J, Wu L, Hosoi K, Yu S, Huang C, Wei H and Chen G: Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Ecotoxicol Environ Saf. 222:1125312021. View Article : Google Scholar : PubMed/NCBI
27	Daugrois C, Bessiere C, Dejean S, Anton-Leberre V, Commes T, Pyronnet S, Brousset P, Espinos E, Brugiere L, Meggetto F and Lamant L: Gene expression signature associated with clinical outcome in ALK-positive anaplastic large cell lymphoma. Cancers (Basel). 13:55232021. View Article : Google Scholar : PubMed/NCBI
28	Chen MT, Fu XH, Huang H, Wang Z, Fang XJ, Yao YY, Ren QG, Chen ZG and Lin TY: Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Leuk Lymphoma. 62:571–580. 2021. View Article : Google Scholar : PubMed/NCBI
29	Peng X, Xiong X, Li Y, Feng C, Liu H, Wu P, Li C and Weng W: Encouraging early outcomes of treatment with arsenic trioxide combined with chemotherapy for alveolar rhabdomyosarcoma in children: 4 Case reports. Front Oncol. 11:7516232021. View Article : Google Scholar : PubMed/NCBI